Clinical Trials · NCT04126070
Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors
- Phase
- Phase 2
- Recruitment status
- Active Not Recruiting
- Sponsor
- Xiao X. Wei, MD
- Enrollment
- 47
- Start date
- May 2020
- Locations
- 6 sites, United States
- Primary endpoint
- Percentage of Subjects With Prostate Specific Antigen (PSA) Less Than or Equal to 0.2 ng/mL at 7 Months From Start of Chemoimmunotherapy